Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Levocarnitine). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Karnitor is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Levocarnitine tablet, Adults: 330 mg two or three times daily, depending on clinical response. Infants and children: 50 to 100 mg/kg/day in divided doses, with a maximum of 3 g/day. Dosage should begin at 50 mg/kg/day, and the exact dosage will depend on clinical response. Levocarnitine solution (for oral use only, not for parenteral use), Adults: The recommended dosage of Levocarnitine 100 ml solution is 10 to 30 ml/day. Higher doses should be administered with caution. Dosage should be started at 10 ml/day and be increased slowly while assessing tolerance and therapeutic response. Infants and children: The recommended dosage of Levocarnitine 100 ml solution is 50 to 100 mg/kg/day. Dosage should be started at 50 mg/kg/day and be increased slowly to a maximum of 30 ml/day. Levocarnitine oral solution can be given from 2 spoonful to 6 spoonful in divided dose as directed by physicians. Higher doses should be administered with caution. Note: Levocarnitine 100 ml solution may be consumed alone or dissolved in drink or other liquid food. Doses should be spaced evenly throughout the day, preferably during or following meals, and should be consumed slowly in order to maximize tolerance.
Side Effects
Carniten is usually well tolerated. A few people may notice mild, temporary side effects such as nausea, vomiting, abdominal cramps, or diarrhoea.
Cautions & Contraindications
Warnings & Precautions
Gastrointestinal reactions may result from taking Carniten too quickly. The safety and efficacy of oral Carniten has not been evaluated in patients with renal insufficiency. Chronic use of high-dose oral Carniten in patients with severely compromised renal function, or in ESRD patients on dialysis, may lead to accumulation of the potentially toxic metabolites trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine.